DOI QR코드

DOI QR Code

Facile Docking and Scoring Studies of Carborane Ligands with Estrogen Receptor

  • Received : 2012.12.24
  • Accepted : 2013.01.08
  • Published : 2013.04.20

Abstract

Closo-carborane has been considered as an efficient boron-carrier for boron neutron capture therapy (BNCT) and an attractive surrogate of lipophilic phenyl or cyclohexyl ring in drug design. Despite a great number of carborane-containing ligands have been synthesized and evaluated, molecular modeling studies of carborane ligands with macromolecules have been rarely reported. We herein describe a facile docking and scoring-function strategy of 16 carborane ligands with an estrogen receptor by using the commercial Gaussian, Chem3D Pro and Discovery Studio (DS) computational programs. Docked poses of the carborane ligands in silico exhibited similar binding modes to that of the crystal ligand in the active site of estrogen receptor. Score analysis of the best docked pose for each ligand indicated that the Ligscore1 and the Dockscore have a moderate correlation with in vitro biological activity. This is the first report on the scoring-correlation studies of carborane ligands with macromolecules. The integrated Gaussian-DS approach has a potential application for virtual screening, De novo design, and optimization of carborane ligands in medicinal chemistry.

Keywords

References

  1. Issa, F.; Kassiou, M.; Rendina, L. M. Chem. Rev. 2011, 111, 5701. https://doi.org/10.1021/cr2000866
  2. Scholz, M.; Hey-Hawkins, E. Chem. Rev. 2011, 111, 7035. https://doi.org/10.1021/cr200038x
  3. Soloway, A. H.; Tjarks, W.; Barnum, B. A.; Rong, F. G.; Barth, R. F.; Codogni, I. M.; Wilson, J. G. Chem. Rev. 1998, 98, 1515. https://doi.org/10.1021/cr941195u
  4. Hawthorne, M. F. Angew. Chem. Int. Edit. 1993, 32, 950. https://doi.org/10.1002/anie.199309501
  5. Ohta, K.; Ogawa, T.; Suzuki, T.; Ohta, S.; Endo, Y. Bioorg. Med. Chem. 2009, 17, 7958. https://doi.org/10.1016/j.bmc.2009.10.018
  6. Ogawa, T.; Ohta, K.; Yoshimi, T.; Yamazaki, H.; Suzuki, T.; Ohta, S.; Endo, Y. Bioorg. Med. Chem. Lett. 2006, 16, 3943. https://doi.org/10.1016/j.bmcl.2006.05.032
  7. Endo, Y.; Yoshimi, T.; Miyaura, C. Pure Appl. Chem. 2003, 75, 1197. https://doi.org/10.1351/pac200375091197
  8. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Fukasawa, H.; Miyaura, C.; Inada, M.; Kubo, A.; Itai, A. Chem. Biol. 2001, 8, 341. https://doi.org/10.1016/S1074-5521(01)00016-3
  9. Fujii, S.; Ohta, K.; Goto, T.; Oda, A.; Masuno, H.; Endo, Y.; Kagechika, H. Med. Chem. Comm. 2012, 3, 680. https://doi.org/10.1039/c2md00294a
  10. Goto, T.; Ohta, K.; Fujii, S.; Ohta, S.; Endo, Y. J. Med. Chem. 2010, 53, 4917. https://doi.org/10.1021/jm100316f
  11. Ohta, K.; Goto, T.; Fijii, S.; Suzuki, T.; Ohta, S.; Endo, Y. Bioorg. Med. Chem. 2008, 16, 8022. https://doi.org/10.1016/j.bmc.2008.07.055
  12. Ohta, K.; Goto, T.; Fujii, S.; Kawahata, M.; Oda, A.; Ohta, S.; Yamaguchi, K.; Hirono, S.; Endo, Y. Bioorg. Med. Chem. 2011, 19, 3540. https://doi.org/10.1016/j.bmc.2011.04.017
  13. Calvaresi, M.; Zerbetto, F. J. Chem. Inf. Model. 2011, 51, 1882. https://doi.org/10.1021/ci200216z
  14. Tiwari, R.; Mahasenan, K.; Pavlovicz, R.; Li, C. L.; Tjarks, W. J. Chem. Inf. Model 2009, 49, 1581. https://doi.org/10.1021/ci900031y
  15. Montes, M.; Miteva, M. A.; Villoutreix, B. O. Proteins 2007, 68, 712. https://doi.org/10.1002/prot.21405
  16. Warren, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. J. Med. Chem. 2006, 49, 5912. https://doi.org/10.1021/jm050362n
  17. Reynolds, R. C.; Campbell, S. R.; Fairchild, R. G.; Kisliuk, R. L.; Micca, P. L.; Queener, S. F.; Riordan, J. M.; Sedwick, W. D.; Waud, W. R.; Leung, A. K. W.; Dixon, R. W.; Suling, W. J.; Borhani, D. W. J. Med. Chem. 2007, 50, 3283. https://doi.org/10.1021/jm0701977
  18. Cigler, P.; Kozisek, M.; Rezacova, P.; Brynda, J.; Otwinowski, Z.; Pokorna, J.; Plesek, J.; Gruner, B.; Doleckova-Maresova, L.; Masa, M.; Sedlacek, J.; Bodem, J.; Krausslich, H. G.; Kral, V.; Konvalinka, J. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 15394. https://doi.org/10.1073/pnas.0507577102
  19. Fujii, S.; Masuno, H.; Taoda, Y.; Kano, A.; Wongmayura, A.; Nakabayashi, M.; Ito, N.; Shimizu, M.; Kawachi, E.; Hirano, T.; Endo, Y.; Tanatani, A.; Kagechika, H. J. Am. Chem. Soc. 2011, 133, 20933. https://doi.org/10.1021/ja208797n
  20. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M. Nature 1997, 389, 753. https://doi.org/10.1038/39645

Cited by

  1. Ciprofloxacin containing Mannich base and its copper complex induce antitumor activity via different mechanism of action vol.45, pp.5, 2014, https://doi.org/10.3892/ijo.2014.2611
  2. The antitumor mechanism of di-2-pyridylketone 2-pyridine carboxylic acid hydrazone and its copper complex in ROS generation and topoisomerase inhibition, and hydrazone involvement in oxygen-catalytic iron mobilization vol.47, pp.5, 2015, https://doi.org/10.3892/ijo.2015.3158
  3. Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-31030-3
  4. In silico prediction coupled with in vitro experiments and absorption modeling to study the inclusion complex of telmisartan with modified beta-cyclodextrin vol.91, pp.1-2, 2018, https://doi.org/10.1007/s10847-018-0797-x
  5. Effects of Substitution of Carboxyl with Hydrazide Group on Position 3 of Ciprofloxacin on its Antimicrobial and Antitumor Activity vol.9, pp.7, 2013, https://doi.org/10.3923/ijp.2013.416.429
  6. The Cytotoxicity of Benzaldehyde Nitrogen Mustard-2-Pyridine Carboxylic Acid Hydrazone Being Involved in Topoisomerase II α Inhibition vol.2014, pp.None, 2013, https://doi.org/10.1155/2014/527042
  7. Antitumor activity of a novel dual functional podophyllotoxin derivative involved PI3K/AKT/mTOR pathway vol.14, pp.9, 2013, https://doi.org/10.1371/journal.pone.0215886